HANGZHOU, China--(BUSINESS WIRE)--Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, today announced that its Co-Founder and Chief Executive Officer, Dr. Luhan Yang, has been selected for the Technology Leaders Initiative (TLI) of the Aspen Institute. Dr. Yang is one of 22 leaders chosen for the initiative’s inaugural global cohort.

Founded in 1949, the Aspen Institute is a global nonprofit organization dedicated to driving change through dialogue, leadership, and action. Through its leadership development programs and cross-sector convenings, the Institute seeks to unlock human potential, address society's most pressing challenges, and create new possibilities for a better world.

The Technology Leaders Initiative builds on this tradition by bringing together founders, CEOs, policymakers, and other leaders who serve in influential roles across the global technology ecosystem. Participants are selected through a rigorous nomination process based not only on their professional accomplishments but also on their demonstrated commitment to using leadership and innovation to advance the public good. The highly selective, two-year leadership program brings together senior leaders from across the global technology ecosystem to explore the ethical, societal, and leadership challenges shaping the digital age.

“I look forward to engaging with fellow leaders in artificial intelligence and other frontier technologies to examine the purpose, boundaries, and responsibilities of innovation through the enduring perspectives of ethics and philosophy,” said Dr. Luhan Yang. “Together, I hope we can translate these insights into action and help ensure that technological innovation serves humanity’s long-term well-being.”

Launched in 2026 as part of the Aspen Global Leadership Network, TLI’s inaugural cohort includes 22 leaders from major technology companies, government digital-governance institutions, financial organizations, and pioneering research groups. Members of the inaugural cohort include Aseem Datar, Chief Product Officer & Corporate Vice President, Microsoft Corporation; Irina Kofman, Vice President, Strategic Initiatives & Operations, OpenAI; Lisa Gevelber, Chief Marketing Officer, Americas, Google; Founder, Grow with Google; Kai Fong Chng, Permanent Secretary, Singapore Ministry of Digital Development and Information; and Leke Osinubi, Partner & Chief Digital Risk Officer, Goldman Sachs; Chief Information Security Officer, GS Bank USA, among other distinguished leaders across technology, public policy, governance, and ethics.

About the Technology Leaders Initiative
The Technology Leaders Initiative is a program of the Aspen Global Leadership Network designed to support influential leaders in the global technology ecosystem as they navigate the concentrated power, ethical complexity, and global trust gaps defining the digital age. The two-year program brings together senior technology leaders for structured dialogue, reflection, and collaboration to meet the leadership needs of the new digital age. https://www.aspeninstitute.org/programs/tech-leaders-initiative/

About Qihan Biotech
Qihan Biotech is a clinical-stage biotechnology company headquartered in Hangzhou, China, founded by Dr. Luhan Yang and Dr. George Church. The company is advancing off-the-shelf cell therapies through multiplex genome editing, synthetic biology, and scalable GMP manufacturing. Qihan’s mission is to transform the treatment of severe diseases by integrating multiplex gene editing, hypoimmunity engineering, and targeted in vivo delivery, unlocking universally accessible cell therapies.

Forward-looking Statements
This release contains statements including, but not limited to, Qihan’s research development and/or relevant programs, its past, ongoing, and planned research studies, and the potential of Qihan’s research candidate. These and any other statements in this release are based on Qihan management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such statements. These risks and uncertainties include, but are not limited to, the risk that Qihan’s research program may not warrant further development, the risk that results observed in prior studies of Qihan’s research candidates will not be observed in ongoing or future studies involving these candidates, the risk of a delay or difficulties in the developing or transforming of Qihan’s research candidates, the risk that Qihan may cease or delay the research development of any of its candidates for a variety of reasons. Qihan is providing the information in this release as of this date and does not undertake any obligation to update any statements contained in this release as a result of new information, future events, or otherwise. Information concerning therapies and related products contained herein is not intended as medical advice.

Media:

Qihan Biotech Public Relations

Tel: +86 0571-83500380

Fax: +86 0571-83500370

media@qihanbio.com

Source: Hangzhou Qihan Biotech Co., Ltd.